Medpace Holdings, Inc.

Medpace Holdings, Inc. is a global clinical contract research organization (CRO) that provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company's mission is to accelerate the global development of safe and effective medical therapeutics. Medpace focuses on delivering full-service Phase I-IV clinical development services, emphasizing a disciplined operating model and therapeutic expertise to provide timely and cost-effective results. Medpace aims to be a partner of choice for small and mid-sized biopharmaceutical companies, consistently utilizing its full-service, disciplined operating model to deliver high-quality results. The company's business strategy involves expanding its market share in the growing Phase I-IV CRO market by conducting clinical trials across all major therapeutic areas. Medpace demonstrates particular strength in Oncology, Metabolic, Cardiology, Antiviral and Anti-infective (AVAI), and Central Nervous System (CNS). The company generates revenue by offering a full suite of services that support the entire clinical development process, from Phase I to Phase IV, across various therapeutic areas. Before a new drug can be commercialized, it typically undergoes extensive pre-clinical and clinical testing and regulatory review to verify safety and efficacy. Medpace's services include a medical department with therapeutic leads who provide strategic direction for study design and planning, train operational staff, work with primary investigators, offer medical monitoring, and meet with regulatory agencies. Clinical trial management is led by clinical trial managers (CTMs) who oversee all aspects of study execution and drive accountability. CTMs utilize ClinTrak, Medpace's proprietary information management system for clinical trials, which is integrated with standard operating procedures (SOPs) to provide real-time study metrics.